Biomarkers and assessment of drug efficacy in cardiovascular disease

Autor: Smink, Paul Arthur

In de afgelopen jaren hebben verscheidene geneesmiddelenstudies, met als doel het onderzoeken of een nieuw geneesmiddel de incidentie van renale en cardiovasculaire complicaties verlaagt, geen beschermend effect kunnen aantonen. Deze resultaten werde

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::b721d018a054cb55eca923cf3380bb26
https://research.rug.nl/en/publications/760a507b-d19a-44bf-bd18-2b4d0072b261

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.

Autor: Schievink B; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands., de Zeeuw D; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands., Smink PA; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands., Andress D; Renal Clinical Development, Abbvie, North Chicago, USA., Brennan JJ; Renal Clinical Development, Abbvie, North Chicago, USA., Coll B; Renal Clinical Development, Abbvie, North Chicago, USA., Correa-Rotter R; National Medical Science and Nutrition Institute Salvador Zubiran, Mexico City, Mexico., Hou FF; Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou, China., Kohan D; Division of Nephrology, University of Utah Health Sciences Center, Salt Lake City, USA., Kitzman DW; Cardiology Section, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, USA., Makino H; Okayama University Hospital, Japan., Parving HH; Department of Medical Endocrinology Rigshospitalet, University Hospital of Copenhagen, Denmark., Perkovic V; The George Institute for International Health, The University of Sydney, Australia., Remuzzi G; IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Centro Anna Maria Astori, Bergamo, Italy; Unit of Nephrology, Dialysis and Transplantation, AO Papa Giovanni XXIII, Bergamo, Italy., Tobe S; Sunnybrook Health Sciences Center, Toronto, Canada., Toto R; University of Texas Southwestern Medical Center, Dallas, USA., Hoekman J; Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, The Netherlands., Lambers Heerspink HJ; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands H.J.Lambers.Heerspink@umcg.nl.

Publikováno v: European journal of preventive cardiology [Eur J Prev Cardiol] 2016 May; Vol. 23 (7), pp. 758-68. Date of Electronic Publication: 2015 Jul 30.